Autoimmune Disease Therapeutics Market Boost due to increase in incidence of autoimmune disease, surge in adoption of autoimmune disease therapeutics by 2025.

According to a new report published by Allied Market Research, titled,"Autoimmune Disease Therapeutics Market by Drug Class, Indication, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018 - 2025," the global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is expected to reach $153,320 million by 2025, growing at a CAGR of 4.2% from 2018 to 2025.

Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/5185?utm_source=openpr&utm_medium=Niranjan

Autoimmune disease therapeutics include different types of drugs such as anti-inflammatory, antihyperglycemics, NSAIDs, interferons, immune suppressants, corticosteroids, beta-blockers, and others. The demand for autoimmune disease therapeutics is estimated to increase during the forecast period owing to a surge in the prevalence of the autoimmune disease, advancement in screening & diagnosis procedures, and wide availability of advanced therapeutics. Moreover, the strong presence of pipeline drugs such as tocilizumab, baricitinib, certolizumab, secukinumab, etanercept, olokizumab, abatacept, apremilast, PF-06438179, golimumab, ustekinumab, etrolizumab, tofacitinib, and others is expected to further boost the market growth.

Based on drug class, the global autoimmune disease therapeutics market is segmented into anti-inflammatory, antihyperglycemics, NSAIDs, interferons, and others. Anti-inflammatory was the major revenue contributing segment in 2017 and is expected to maintain its dominance during the forecast period owing to increase in demand for anti-inflammatory drugs, the launch of newer anti-inflammatory drugs with the supportive reimbursement policies for usage of advanced anti-inflammatory drugs in some countries. Moreover, the expected launch of pipeline anti-inflammatories such as tocilizumab, certolizumab, secukinumab, etanercept, golimumab, and others, is estimated to further influence market growth.

Based on indication, the market is classified as rheumatic disease, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and other indications. Rheumatic disease segment accounted for a major share in 2017 and is expected to remain dominant during the forecast period owing to surge in prevalence of arthritis, fibromyalgia, systemic lupus erythematosus, gout, scleroderma, polymyalgia rheumatica and others, wide availability of advanced therapeutics for treatment of rheumatic disease, availability of advanced therapeutics for the treatment of these diseases.

Purchase Inquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/5185?utm_source=openpr&utm_medium=Niranjan

According to the sales channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online stores. Online providers segment is expected to experience rapid growth during the forecast period owing to rise in preference for online purchasing of drugs over the traditional methods and increase in awareness about online pharmacy with rising in the number of internet users. On the other side, drug store & retail pharmacy segment is estimated to be the major revenue contributor due to the massive presence of these pharmacies.

Key Findings of the Autoimmune Disease Therapeutics Market:
• Based on indication, the rheumatic disease segment held nearly half of the global market share in 2017 and is projected to grow at a CAGR of 5.2% from 2018 to 2025.
• Based on the sales channel, the online stores' segment is expected to experience rapid growth and is projected to grow at a CAGR of 6.8% during the forecast period 2018-2025.
• Depending on drug class, the anti-inflammatory segment accounted for nearly half of the global market share in 2017 and is projected to grow at a CAGR of 5.2% from 2018 to 2025.
• Based on the region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.3% during the forecast period.

North America accounted for a major market share in 2017 and is expected to remain dominant throughout the forecast period. Higher prevalence of the autoimmune disease, early diagnosis, easy availability of advanced therapeutics, a strong presence of key players, favorable reimbursement in the healthcare system, and the higher number of trained medical professionals are key drivers of the North America autoimmune disease therapeutics market.

On the other side, Asia-Pacific is expected to experience the highest growth rate during the forecast period owing to the increase in the number of the target population, rise in adoption of therapeutics with development in healthcare infrastructure.

About Us:-

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact Us:-

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.